Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > What's Going to happen to B Warrants on April 26th!

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Feb 24, 2022 12:43pm

99 Views

Post# 34458572

RE:RE:RE:What's Going to happen to B Warrants on April 26th!

Whyme16 wrote: Red~One, they were issued and shareholders purchased them based on the FALSE PROMISES these f ers made! IF this is not considered FRAUD, then what is???

Would it be possible to EXTEND THEM since NONE of the MILESTONES promissed materialize??

It would make more sense if their expiration was likned to progress made.

THIEVES have more mercy than SALZMAN! What a shame.

Because the B warrants are tradable TSX rules are that they cannot be extended. Unless someone knows different.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale